Marshall Wace’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
– Sell
-360,293
Closed -$1.1M – 2890
2023
Q4
$1.1M Sell
360,293
-156,435
-30% -$294K ﹤0.01% 1439
2023
Q3
$744K Buy
516,728
+461,128
+829% +$892K ﹤0.01% 1591
2023
Q2
$138K Sell
55,600
-707,776
-93% -$1.93M ﹤0.01% 2293
2023
Q1
$2.05M Sell
763,376
-231,612
-23% -$1.11M ﹤0.01% 1449
2022
Q4
$5.4M Buy
994,988
+362,810
+57% +$3.04M 0.01% 1141
2022
Q3
$7.9M Buy
632,178
+155,356
+33% +$1.77M 0.02% 1063
2022
Q2
$2.36M Buy
476,822
+377,801
+382% +$2.09M ﹤0.01% 1879
2022
Q1
$753K Buy
+99,021
New +$939K ﹤0.01% 2579
2020
Q1
– Sell
-17,944
Closed -$474K – 2146
2019
Q4
$474K Buy
+17,944
New +$420K ﹤0.01% 1192
2019
Q3
– Sell
-189,486
Closed -$5.81M – 1975
2019
Q2
$5.81M Buy
189,486
+104,562
+123% +$2.2M 0.05% 432
2019
Q1
$1.41M Sell
84,924
-301,586
-78% -$5.72M 0.01% 837
2018
Q4
$7.4M Buy
386,510
+342,990
+788% +$12.8M 0.08% 330
2018
Q3
$2.28M Buy
+43,520
New +$2.37M 0.02% 651

Other funds holding GTHX

Marshall Wace's GTHX Position: Q1 2024 in Review

Marshall Wace sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q1 2024, closing a stake of 360,293 shares — an estimated $1.1M sold.

Marshall Wace first reported a position in GTHX in Q3 2018 and held it in 13 quarters. The position peaked at $7.9M in Q3 2022. 86 funds tracked by Wall St. Rank hold GTHX as of Q1 2024.

  • Marshall Wace reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Marshall Wace sold 360,293 G1 Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $1.1M.
  • Marshall Wace first reported a position in G1 Therapeutics, Inc. Common Stock in Q3 2018 and held it in 13 quarters.
  • Marshall Wace's G1 Therapeutics, Inc. Common Stock position peaked at $7.9M in Q3 2022.
  • 86 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Marshall Wace's 13F filing for Q1 2024, filed 15 May 2024.